Effective chemotherapy for hormone-refractory prostate cancer (HRPC): Present status and perspectives with taxane-based treatments

Possible roles of vinexinβ in growth and paclitaxel sensitivity in human prostate cancer PC-3 cells

“…11,12 Although anti-microtubule agents such as taxanes-based chemotherapy agents are widely used for treatment of androgen-independent prostate cancer, chemoresistance is a major hurdle. 19,20 We studied role(s) of vinexinb in (C) 2 × 10 5 cells were cultured for 24 h followed by incubation with 100 nM paclitaxel for 48 h. Cells were harvested and genomic DNA extracted from cells was subjected to 2.0% agarose gel electrophoresis. Three independent experiments gave similar results.…”

Highlights of Natural Products in Prostate Cancer Drug Discovery

“…Phase I clinical trials of ixabepilone administered i.v. as a 1 hour infusion daily, for 5 consecutive days every 21 days, at doses of 1.5 mg/m 2 /day, displayed antitumor responses in patients with prior taxane treatment against solid tumors (Mancuso et al, 2007). Major adverse effects were neutropenia and neuropathy.…”

“…Ixabepilone was also evaluated as a single agent in two first line studies. PSA response was observed in 30-35% of cases with an objective clinical response rate of over 15% in patients with measurable disease (Mancuso et al, 2007). When combined with estramustine phosphate (ixabepilone 35 mg/m 2 i.v.…”

“…Although patients with ixabepilone-refractory disease were less likely to respond to second-line taxane chemotherapy, 36% did achieve a PSA response. For patients with taxane-resistant HRPC, a randomized phase II study compared ixabepilone to mitoxantrone/ prednisone (Mancuso et al, 2007). A PSA decline of over 50% was seen in 20% of patients and median survival of 13 months was found for patients on the mitoxantrone arm, as compared to a PSA decline of over 50% in 17% and median survival of 12 months for ixabepilone treatment (Mancuso et al, 2007.…”

“…Patients with CRPC are currently treated with docetaxel ( Fig. 5) chemotherapy and prednisone which improves survival time in about 18 months (Mancuso et al, 2007, Harzstark & Small, 2010. Nonetheless, patients with CRPC will die of their cancer and thus new treatments are required (Lassi & Dawson, 2010, Sartor, 2011.…”